KMT2A and acute lymphoblastic leukemia: They also found that MEIS1 expression was particularly sensitive to MI-3454 treatment in KMT2A-r ALL, identifying MEIS1 expression as a potential pharmacodynamic biomarker for the clinical translation of Menin-KMT2A inhibitors [94].